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groups were investigated: (1) The effect of NK depletion (with the
depleting antibody, PK136) on engraftment and tolerance was
determined. (2) The effect of NK depletion on engraftment efﬁ-
ciency was tested by transplanting in the presence or absence of
busulfan. (3) We determined if blocking NK signalling with the
anti-adhesion antibody anti-LFA1 could produce effects on en-
graftment similar to those observed with whole-scale NK deple-
tion. Results: (1) Animals with unmanipulated NK cells exhibited
costimulation-blockade resistant rejection when transplanted with
5  106 donor cells. However, NK depletion promoted stable
chimerism even when very low doses of donor marrow (0.5  106)
were infused. The chimeric animals in both the NK replete and
NK-depleted groups were tolerant to their allografts: they exhib-
ited deletion of donor-reactive v5 and v8 CD4 cells and
accepted Balb/C skin grafts. (2) NK depletion had a powerful effect
on engraftment efﬁciency: NK depletion promoted engraftment
even in the absence of busulfan. (3) Blocking NK function with the
anti-LFA1 antibody had the same effect as whole-scale NK deple-
tion with PK136: treated animals became stably chimeric and
tolerant even when very low doses of donor marrow were infused.
Implications: These data highlight the central role that NK cells
play in rejection of allogeneic bone marrow and underscores the
need to control NK alloreactivity during clinical transplantation.
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A MULTI-INSTITUTIONAL STUDY OF EXTRACORPOREAL PHOTOIM-
MUNE THERAPY (ECP) WITH UVADEX FOR THE PREVENTION OF
ACUTE GVHD IN PATIENTS (PTS) UNDERGOING STANDARD MYELOA-
BLATIVE CONDITIONING AND ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (AHCT)
Abhyankar, S.1; Shaughnessy, P.J.2; Bolwell, B.J.3; van Besien, K.4;
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Study Group. 1. Kansas City Cancer Center, Kansas City, MO; 2. Texas
Transplant Institute, San Antonio, TX; 3. The Cleveland Clinic Foun-
dation, Cleveland, OH; 4. University of Chicago, Chicago, IL; 5. Klinika
Hematologie a Transfuziologie, Bratislavia, Slovakia (Slovak Republic);
6. Royal Melbourne Hospital, Melbourne, Australia; 7. St. Vincents
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Gentil, Lisbon, Portugal; 10. Therakos, Exton, PA; 11. New England
Medical Center, Boston, MA; 12. Hammersmith Hospital Imperial
College School of Medicine, London, United Kingdom.
ECP with UVADEX has shown beneﬁt in pts with acute and
chronic GVHD. ECP has shown to reduce the incidence of
GVHD in a reduced intensity conditioning regiment (Foss. BMT.
2004 May). We report preliminary results of the ﬁrst multi-insti-
tutional phase 2 study examining ECP with a standard myeloab-
lative preparative regimen prior to AHCT. ECP was given on 2
consecutive days between D-10 and D-6, followed by cyclophos-
phamide 60 mg/kg/day for 2 days and TBI 1200 cGy over 3 days.
GVHD prophylaxis was Cyclosporine 3–5 mg/kg IV daily begin-
ning D-1, and later switched to PO, adjusted to keep levels 200–
600 ng/ml, and methotrexate 10 mg/m2 on D1, 3, 6, and 11 for pts
who had matched unrelated donors (MUD) or HLA class 1 one-
antigen mismatched related donors (MMRD), or 10 mg/m2 on D1
and 5 mg/m2 on D3, 6, and 11 for pts who had matched related
donors (MRD). Enrollment has been completed and data are
available on 61 of 65 pts. The median age was 39 (20–60) years and
40 (66%) pts were male. Diagnoses included AML/MDS (n20),
ALL (n14), CML (n16), lymphoma (n5), CLL (n3), and
other (n3). 29 pts had MRD, 31 MUD, and 1 MMRD. 28 pts
received bone marrows and 33 patients had PBPC for their trans-
plant. All patients engrafted. Acute GVHD grade 2–4 occurred in
11 (37.9%) pts and grade 3–4 occurred in 2 (7%) pts, who received
MRD transplants (n29); and grade 2–4 in 16 (51.6%) pts and
grade 3–4 in 10 (32.3%) pts, who received MUD transplants
(n31). No aGVHD occurred in 1 pt who received a MMRD
transplant. Mild reversible hypotension related to ECP occurred in
1 pt who was able to continue on study. Chronic GVHD occurred
in 23 of 61 evaluable pts; limited in 15, extensive in 6, and unknown
in 2 pts. There are 43 (70.5%) pts alive at a median follow up of
303 (168–560) days. Actuarial estimates of survival at one year are
83% for pts who received MRD transplants and 63% for pts who
received MUD or MMRD transplants. Causes of death include
relapse (n5), aGVHD (n3), multi-organ-system-failure (n3),
pneumonitis (n4, interstitial/CMV/aspergillus), and 1 each of
infection, neurologic toxicity, and arterial thrombosis. Preliminary
results of this study reveal no adverse affects of ECP on regimen
related toxicity or engraftment after a standard myeloablative
AHCT. The overall survival of pts in this trial is encouraging and
warrants further study.
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HUMAN HERPESVIRUS 6 MANIFESTING AS ENCEPHALITIS IN HEMA-
TOPOIETIC PROGENITOR CELL RECIPIENT AFTER REDUCED INTEN-
SITY ALLOGENEIC TRANSPLANTATION
Ng, N.; Devoe, C.; John, V.; Bayer, R.-L. North Shore-LIJ Health
Systems, Manhasset, NY.
Diagnosis of active Human Herpesvirus 6 (HHV-6) infection in
Hematopoietic Progenitor Cell (HPC) recipients can be difﬁcult
because the virus is ubiquitous and persistent in the human body.
HHV-6 infection usually occurs within 2 to 4 weeks following
transplantation. Infection with HHV-6 can be primary infection or
reactivation. Viral infection can result in clinical symptoms includ-
ing fever, rash, pneumonia, bone marrow suppression, encephalitis
and rejection. There is also a possible correlation between graft
versus host disease and HHV-6. We report a case of a 50 year old
male with a history of refractory Acute Myelogenous Leukemia
(AML). The patient was induced with Etoposide, Ara-C and
Daunorubicin. He relapsed despite consolidation chemotherapy
with HiDAC and Etoposide. He underwent other inductions with-
out lasting response. Bone marrow biopsy after Myelotarg and
HiDAC was hypocellular and he was taken directly to transplan-
tation. The patient underwent a 5/6 HLA mismatched sibling
donor transplant. The preparative regimen included Fludarabine
25 mg/m2/d  5, Melphalan 70 mg/m2/d  2 and ATG. His
GVHD prophylaxis included Cyclosporine and Methotrexate. The
patient engrafted on day 23. Donor chimerism was 100% on day
30. Approximately 3 weeks after transplant, the patient developed
fever, severe myoclonus, mental status changes and amnesia. A
brain MRI showed temporal lobe enhancement. Lumbar puncture
revealed total protein of 58 mg/dL, glucose 80 mg/dL, WBC
1/L, and RBC 1940/L. HHV-6 IgG was 1:320 and IgM was
negative prior to transplantation. The patient required intubation
and blood pressure support. He was treated with IVIG weekly and
Acyclovir initially. Multiplex RT-PCR analysis (Argene, Inc.) of
the CSF was positive for HHV-6. The patient was started on
ganciclovir when the data was obtained; however his status had
improved prior to the change in medications. Follow-up HHV-6
titers 4 weeks after decompensation revealed HHV-6 IgG 1:1280.
The patient developed grade 2–3 GVHD of the gut approximately
day 55. Based on the MRI ﬁndings, the PCR positivity of the spinal
ﬂuid and the amnesia, we suspect that this is active HHV-6 infec-
tion. There have been several cases of encephalitis due to HHV-6
in HPC transplant patients who have presented with amnesia and
who have temporal enhancement on MRI. HHV-6 can be a serious
pathogen in HPC recipients receiving reduced-intensity prepara-
tive regimens.
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PERI-TRANSPLANT IMATINIB ADMINISTRATION RESULTS IN SIGNIFI-
CANT MORTALITY OF RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTS DUE TO IMPAIRED BONE MARROW RECOV-
ERY
Keating, A.R.; McGoldrick, S.; Kochman, A.; Eng, J.M.; Hubbard,
V.M.; van den Brink, M.R.M. Memorial Sloan Kettering Cancer Cen-
ter, New York, NY.
Allogeneic hematopoietic stem cell transplantation (HSCT) is
the only known cure for chronic myeloid leukemia (CML). Ima-
tinib mesylate is able to induce a complete hematologic response in
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